A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ECOG-ACRIN E4512)
This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Principal Investigator(s)
Salvatore Del Prete, MD
Sponsor(s)
National Cancer Institute
Contact
Ed Hatton, RN at 203-358-8879 or [email protected]
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695
Stamford, CT 06902
Main: 203-276-2695